COVID-19
Management Guidelines

2020
Message by President Pakistan Chest Society

Pandemic of Coronavirus disease 2019 (COVID-19) has grasped the world including Pakistan. As the virus is new and the dynamic of human involvement is not known so it is difficult to design strategy to overcome this threat. The country is trying to follow the path of prevention (lockdown, physical but not social distancing, hand washing, droplet and contact precautions etc) but at the same time we need to devise concentrated efforts to treat the disease/infection.

Pakistan Chest Society (PCS) decided to take meaningful steps in this scenario and the PCS guideline committee voluntarily took the lead. I would like to congratulate PCS guideline committee for developing this guideline on "COVID-19".

The guideline was prepared on war footing basis and the committee was able to bring this guideline in just one week time. I appreciate the sincere efforts done by each member.

I am hopeful that this concise guideline will be of great help and ready reference for health care professionals involved in the management of such patients. It will also be useful for under & postgraduate students and the nursing staff.

PROFESSOR. DR. NISAR AHMED RAO

President,
Pakistan Chest Society

28 March 2020
Guidelines on Management of Patients with COVID-19

March 2020

Pakistan Chest Society (PCS) Guidelines Working Group:

Professor Muhammad Irfan
Professor, Pulmonary and Critical Care Medicine
Aga Khan University Hospital, Karachi, Pakistan.
muhammad.irfan@aku.edu

Professor Talha Mahmud
Head, Department of Pulmonology
Shaikh Zayed Hospital, FPGMI, Lahore, Pakistan.
drmtalha@hotmail.com

Professor Saadia Ashraf
Head, Department of Pulmonology
Khyber Teaching Hospital Peshawar, Pakistan.
sadiaashraf1@gmail.com

Dr. Maqbool Ahmed Langove
Assistant Professor, Department of Pulmonology
Fatima Jinnah Chest Hospital Quetta, Pakistan.
amaqboola93@gmail.com

Professor Ali Bin Sarwar Zubairi
Section Head, Pulmonary and Critical Care Medicine,
Aga Khan University Hospital, Karachi, Pakistan.
ali.zubairi@aku.edu

Professor Mukhtiar Zaman Afridi
Head, Department of Pulmonology, Rehman Medical Institute,
Principal Rehman Medical College Peshawar, Pakistan.
mza38@hotmail.com

Professor Nisar Ahmed Rao
Director, Ojha Institute of Chest Diseases,
Dow University of Health Sciences, Karachi, Pakistan.
nisar.rao@aku.edu
Preface

There have been various epidemics in different regions of the world during different time frames. Many were confined to specified regions like Dengue outbreak in Pakistan (2011), Yellow fever outbreak in Sudan (2012), Ebola virus epidemic in West Africa (2013-16), and 2019 measles outbreak in the Democratic Republic of the Congo. The world has also witnessed deadly pandemics like Spanish flu (1918–1920), Asian flu (Influenza A virus subtype H2N2) in 1957–1958, Seventh cholera pandemic (Cholera (El Tor strain) in 1961–1975, Swine flu pandemic (H1N1) in 2009, Middle East respiratory syndrome coronavirus outbreak during 2012 and the current ongoing 2019–2020 coronavirus pandemic (Covid-19).

This is an unprecedented global war, and the entire mankind is fighting against the same enemy identified as SARS CoV-2. This war commenced in December 2019 from Wuhan (China), and was declared a pandemic in March 2020 by the WHO. Every physician and epidemiologist is staring at the same question — how and when is will be eradicated from the world? It seems to be the beginning of the end or perhaps the end of the beginning in China, while in other regions like the USA and Europe and eventually Asia, the pandemic seems to be a harbinger of disaster.

The entire world was naïve about this novel disease’s manifestations, complications, evaluation and management. Isolation, diagnosis, treatment, protective measures, and rehabilitation have all been implemented from scratch. This globally detrimental phenomenon has paved way towards the notion of joining heads and coming up with strategies to help the ailing humanity. At this moment, sharing success experiences and lessons, resources, and knowing what to avoid and what to adopt regardless of who you are, seems to be our only chance of winning this battle. The battle for which the health care facilities are battle fields and health care workers are soldiers. The remedy for this pandemic is not isolation, but cooperation.

This timely written guideline is a quick review for the pulmonary, medical, critical care and related specialties that are evaluating and providing care to suspected or confirmed COVID-19 patients. We strongly pray to Allah and looking forward to see an earlier end to this deadly pandemic from our homeland as well as the entire world.

Very sincerely,

Professor Talha Mahmud

On behalf of PCS Guidelines Working Group
Dedicated

to

the Martyrdom

of

Dr. Osama Riaz

in the line of duty

(Rest in Peace)
Introduction
In December 2019, several cases of pneumonia due to some unknown pathogen were on the rise in Wuhan city, Hubei province of China. It was not till 31st of December 2019 that health authorities in China reported these cases to be investigated further. By this time a number of patients had become victim of severe illness. Soon a viral RNA was detected from bronchoalveolar lavage samples of some of the patients. The genome was sequenced and it was found to be closely related to SARS corona virus. The cases so far detected were linked to a seafood market and was thought to be a zoonotic, which could not be confirmed yet. The disease was named by WHO as COVID-19 caused by SARS-CoV-2. It had started as a single patient on December 1, 2019, then increased rapidly, initially in China, thereafter affecting other countries particularly Iran, Italy, Spain and USA. WHO declared it as a worldwide pandemic on March 11, 2020. Pakistan was not exempted from this pandemic. Till date this potentially deadly virus has infected more than 595,000 people worldwide, and 1400 plus cases are already been reported from Pakistan.
The disease has variable clinical presentation. It can range from mild flu like symptoms to ARDS and sepsis. Mortality is more often reported in elderly population and those with comorbidities. In this situation Pakistan Chest Society is documenting the guidelines for diagnosis and treatment of the disease. Although we are still learning about the disease, Pakistan Chest Society (PCS) is playing its part in current situation.

Definitions (WHO):

**Suspect Case:**
- A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), **AND** a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset; **OR**
- A patient with any acute respiratory illness **AND** having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset; **OR**
- A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; **AND** requiring hospitalization) **AND** in the absence of an alternative diagnosis that fully explains the clinical presentation.

**Probable Case:**
- A suspect case for whom testing for the COVID-19 virus is inconclusive. **OR**
- A suspect case for whom testing could not be performed for any reason.
Confirmed Case:

- A person with lab confirmation of COVID-19 infection irrespective of clinical signs and symptoms.

Contact:

A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case:

- Face-to-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes;
- Direct physical contact with a probable or confirmed case;
- Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment; and
- Other situations as indicated by local risk assessments.

Note: for confirmed asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days after the date on which the sample was taken which led to confirmation.

Clinical Features of COVID-19:

Incubation Period:

Incubation period varies from 1 to 14 days after exposure with most of the patient experiences symptoms on 5th day. In small number of patients, it can be longer than 14 days.

Spectrum of Disease Severity:

Clinical Spectrum of disease ranges from asymptomatic to mild symptoms such as cough, fever, myalgias to pneumonia, acute respiratory distress syndrome, and sepsis with septic shock to multiorgan failure. Most of the cases are self-limiting (80%), however, elderly and patients with comorbidities tend to have more severe disease.

Frequently occurring presenting symptoms are:

- Fever > 100F 44-98%
- Dry Cough (new or worsening) 46-82%
- Shortness of breath (new or worsening) 14-31%
- Myalgia or Fatigue 11-52%

Less common symptoms are:

- Sputum production
- Headache
- Sore throat
- Hemoptysis
- Rhinorrhea
Gastrointestinal symptoms such as nausea & diarrhea may be seen in some as presenting symptoms. Anosmia (loss of smell) is being reported in some cohorts as a presenting symptom occurring even before any other clinical feature, although it has yet to be confirmed.

**Disease can be categorized into mild, moderate, severe and critically ill for appropriate management:**

**Mild Disease:**
These patients usually present with symptoms of:
- An upper respiratory tract viral infection or
- Low grade fever, cough, malaise, rhinorrhea, sore throat without any warning signs and non immunocompromised.

**Moderate Disease:**
- Shortness of breath with respiratory rate > 25
- High grade fever > 100°F
- Hemoptysis (may be)
- Gastro-intestinal symptoms: nausea, vomiting, diarrhea
- Without change in mental status (i.e. confusion, lethargy)
- With or without comorbidities and chest radiograph suggestive of pneumonia

**Severe Disease:**
- Respiratory rate > 30/min
- qSOFA score 2 or more
- SPO₂ ≤ 93%
- PaO₂/FiO₂ <300
- Confusion, agitation, restlessness
- Bilateral lung infiltrates >50% within 24- 48 hours

**Critically ill:**
- Respiratory failure (need of mechanical ventilation)/ARDS
- Septic shock
- Multiorgan dysfunction syndrome (MODS)

**Epidemiological risk factors for severity of disease:**
- Older Age
- Male gender
- Cancer
- Chronic pulmonary diseases
- Cardiovascular disease
- Chronic kidney disease
- Diabetes mellitus
Diagnosis of COVID-19:

After initial evaluation of patients who meet the criteria for suspect cases, (see case definitions, clinical features and triage section) and taking decision for home care and quarantine versus hospitalization, in terms of isolation room/bay or ICU admission, the following diagnostic interventions should be considered:

1. Complete Blood Count (CBC):
   - Leukopenia, leukocytosis, and lymphopenia (most common) can be seen.
   - Hemoglobin and platelets count is mostly preserved.
   - Thrombocytopenia and severe lymphopenia have been associated with mortality.

2. Serum Biochemistry & Inflammatory Markers:
   - Elevated lactate dehydrogenase (LDH) and ferritin levels are common.
   - Deranged LFTs (elevated aminotransferase levels) have also been described.
   - Deranged renal functions (raised serum urea and creatinine levels, and altered electrolytes) are associated with acute kidney injury and are reflective of severe disease.
   - CRP levels mirrors disease severity as are serum procalcitonin levels which may be normal at the time of hospitalization and are more likely to be elevated in subjects requiring critical care admission.
   - High D-dimer levels (>1 mcg/mL), elevated troponin and elevated creatine phosphokinase have been associated with higher mortality.
   - Coagulopathy (elevated prothrombin time), acidosis, raised lactate and hyperbilirubinaemia may be seen in life threatening cases associated with multiorgan dysfunction.

3. SARS-CoV-2 RNA detection by reverse-transcription polymerase chain reaction (RT-PCR): Can be done in any of the following respiratory specimens:
   a) Nasopharyngeal swab specimen (preferable as viral RNA levels may be higher in nasal compared with oral specimens).
   b) Oropharyngeal swab can be collected but is not essential; if collected, it should be placed in the same container as the nasopharyngeal specimen.
   c) Sputum collected only from patients with productive cough.
   d) Tracheal aspirate/bronchial washings/bronchoalveolar lavage: Can be evaluated from patients who are admitted in critical care and require intubation. Specimen can also be utilized to diagnose concomitant infection by other viruses/bacteria/fungi.

A positive RT-PCR test for SARS-CoV-2 confirms the diagnosis of COVID-19 although false-positive and false negative tests are possible. If initial testing is negative but the suspicion for
COVID-19 is high, it is recommended to resample and analyze specimen from multiple respiratory tract sites as above. Negative RT-PCR tests on oropharyngeal swabs despite CT findings suggestive of viral pneumonia have been reported in some patients who later on tested positive for SARS-CoV-2 PCR. The accuracy and predictive values of SARS-CoV-2 testing have not been systematically evaluated. In a recent study of 205 patients with COVID-19 who were sampled at various sites, the highest rates of positive viral RNA tests were reported from BAL (95%) and sputum (72%), compared with oropharyngeal swab (32%). So sputum specimen should be preferred to nasopharyngeal/oropharyngeal swab if patient is actively producing it but should be collected with caution.

*Sputum induction is not recommended and droplet/aerosol and contact precautions must be followed when collecting respiratory specimen from suspected COVID-19 case. Ideally, all respiratory specimen collection procedures should be conducted in negative pressure room if available. For safety reasons, specimens from a patient with suspected or confirmed COVID-19 should not be submitted for viral culture.*

4. Serological Testing:
The role of serology is currently unclear and once recommended and generally available, should be able to identify patients who have either current or previous infection but a negative RT-PCR testing. Large-scale serologic screening in near future may be able to provide a better sense of the scope of asymptomatic infections and inform epidemiologic analysis. In a recent Chinese study, the host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively.

COVID-19 rapid test kits are also becoming available that qualitatively detects IgG and IgM antibodies (lateral flow immuno-chromatography) to SARS-CoV-2 in blood samples. Currently, there is no definitive evidence regarding the utility of rapid diagnostic kits.

5. Radiology:
*Chest radiograph* is usually the first radiological investigation. It may be normal in initial phases. It mostly reveals bilateral lung infiltrates and consolidation. *Chest CT*, low dose non-contrast,may be helpful in making the diagnosis/follow-up and can also reveal presence of complications like ARDS and pleural effusions. No finding can completely rule in or rule out the possibility of COVID-19 pneumonia. Typical chest CT scans most commonly demonstrate ground-glass opacification with or without consolidative abnormalities, consistent with viral pneumonia. The abnormalities tend to be bilateral, exhibit a peripheral distribution, and predominantly may involve the lower lobes (see CT images below). Uncommon findings include pleural effusion and/or thickening, and mediastinal
lymphadenopathy. A "positive" chest CT for COVID-19 carries a sensitivity of 97 percent (using the RT-PCR tests as a reference standard) and specificity is around 25 percent as other etiologies may result in similar radiological findings. Timings of occurrence of radiological abnormalities may be variable; in some patients most severe abnormalities were detected approximately 10 days after symptom onset and in some with minimal respiratory symptoms and even prior to the detection of viral RNA from upper respiratory specimens and the CT findings can be categorized reflective of the disease stage. The provision of dedicated scanner and infection control protocols has to be followed.

CT Images of a 44-year-old man with COVID-19 pneumonia.

**Thoracic ultrasound (TUS)** findings in COVID-19 are non-specific and the role is not well established but it can still be used as a bedside modality without any radiations risk. It has the additional advantage of avoiding transportation of infectious, hypoxemic and hemodynamically unstable suspected or established COVID-19 patients for chest CT to radiology department. TUS findings may include thickening of the pleural line with pleural line irregularity, B lines in a variety of patterns including focal, multifocal, and confluent (interstitial edema), consolidations in a variety of patterns including multifocal small, non-translobar, and translobar with
occasional air bronchograms (pneumonia/ARDS), appearance of A lines during recovery phase and sometimes pleural effusions.

6. Electrocardiogram (ECG) & Echocardiography:
ECG is required for all hospitalized patients to measure baseline QT interval as some subjects may require drugs like chloroquine and/or azithromycin which may cause QT interval prolongation and cardiovascular events. Pre and post drug administration ECG can help recognize subjects who can develop QT interval prolongation as an adverse event related to offending drug. Besides, some very sick patients may develop or present with arrhythmias, acute cardiac injury, and shock and thus may require ECG and echocardiography.

Management of confirmed COVID-19 patients:

<table>
<thead>
<tr>
<th>Severity of Illness</th>
<th>General Management</th>
<th>Drugs*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic Cases</td>
<td>• Strict home isolation for a minimum of 14 days.</td>
<td>Not needed.</td>
</tr>
<tr>
<td></td>
<td>• if develops any symptoms ask to report on helpline.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Repeat PCR on day-14 and If it is negative, discontinue isolation.</td>
<td></td>
</tr>
<tr>
<td>Mild Disease</td>
<td>• Strict home isolation or if not available then in any health care facility with isolation facilities.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Should be placed in a single room. Contact and droplet precautions should be instituted.</td>
<td>• Use paracetamol for fever and avoid ibuprofen or NSAIDs.</td>
</tr>
<tr>
<td>Moderate Disease</td>
<td>• Should be admitted in hospital and placed in a single room.</td>
<td>• Use paracetamol for fever and avoid ibuprofen or NSAIDs.</td>
</tr>
<tr>
<td></td>
<td>• Contact and droplet precautions should be instituted.</td>
<td>• Start Hydroxychloroquine ** loading dose 400 mg BD then 200 mg TDS for 10 days OR Chloroquine 500mg BD x 10 days.</td>
</tr>
</tbody>
</table>
Severe Disease

- Admit the patient preferably in ICU with airborne isolation and strict PPE precautions.
- Hydrate the patient preferably IV according to need and hemodynamic status of patient.
- Oxygen administration via face mask to keep oxygen saturation > 92%
  If unable to maintain saturation, then can try Non Invasive ventilation (NIV) cautiously.
- Regular assessment for need of endotracheal intubation and mechanical ventilation as delay in intubation is associated with unfavorable outcomes.
- If mechanical ventilation is needed, use ARDS NET protocol for ventilatory management.
- Consider prone positioning and ECMO (If available) for refractory hypoxemia.

- Use paracetamol for fever and avoid ibuprofen or NSAIDs.
- Avoid systemic steroids. This can be used only if patient is in septic shock requiring vasopressors (conditional recommendation)
  hydrocortisone 100 mg IV 8 hourly
- Give empiric antimicrobials to treat suspected pathogens according to local settings
- Start Hydroxychloroquine** loading dose 400 mg BD then 200 mg TDS for 10-14 days
  OR
  Chloroquine 500mg BD x 10-14 days
  If patient is not improving or in ARDS, use one or more of the following agents if available with ID consultation:
  1. Tab Lopinavir/Ritonavir
     400/100mg BID 14 days
  2. IV Remdesivir: loading dose 200 mg followed by 100 mg once daily for 10 days
  3. IV Tocilizumab 4-8mg/kg (max dose 800 mg)

It has been clarified that there are currently no registered medicines for the treatment of COVID-19, because no treatment results from therapeutic research have been published. Based on currently available data, the options presented are for patients admitted with COVID-19 due to moderate and severe disease symptoms.

**Combination of Hydroxychloroquine (HCQ) and Azithromycin** HCQ 200 mg TDS and Azithromycin 500 mg loading dose and 250 mg once daily for 4 days was used in one small study in moderate cases with favorable results. So far not enough data is available to recommend this combination therapy. Caution should be taken as this combination therapy can cause prolonged QT interval and Torsade de Pontes. Baseline and daily repeat ECG is recommended whenever this combination is used.17

***Hydroxychloroquine (HCQ) Prophylaxis:** In some countries like India, HCQ is being recommended for prophylaxis in health care workers involved in care of suspected/confirmed cases of COVID-19 (400 mg BD on day 1 followed by 400 mg once weekly for 7 weeks). There is no proven benefit/data available at this moment and most of the authorities are not recommending this prophylaxis.
**Labs Indicating Severe Disease**
- D-dimer >1000
- CPK>2x ULN
- CPR>100
- LDH>245
- Troponin elevated/uptrending
- Abs lymphocyte count <0.8
- Ferritin > 300

**DIAGNOSTICS**

**DAILY LABS**
- CBC with diff (trend lymphocyte count)
- CPK

**RISK START Q2-3 DAY PRN**
- D- dimer
- Ferritin/ CRP/ESR
- LDH
- EKG
- NO ROUTINE DAILY CXR

**HEMODYNAMICS**
- Norepinephrine first choice pressor
- If WORSENING:
  - Consider myocarditis/ Cardiogenic shock
  - Obtain echo, EKG, troponin

**THERAPEUTICS**

**ALL ICU ADMISSIONS**
- Empiric antibiotics
- Start **Hydroxychloroquine** 400 mg BID then 200 mg TID for 10-14 days
  OR
- **Chloroquine** 500mg BD
  And
- If available use one of the following agents with ID consultation
  - 1. IV **Remdesivir**: loading dose 200 mg followed by 100 mg once daily for 10 days
  - 2. **Tab Lopinavir/ritonavir** (LPV/r)
    - 400/100mg BID 14 days
  - 3. **IV Tocilizumab** 4-8mg/kg two doses 12 hourly (max dose 800 mg)

---

**RESPIRATORY FAILURE**

**CONSIDER EARLY INTUBATION IN ICU**

**WARNING SIGNS:** INC FiO₂, DEC SaO₂, Worsening of lung infiltrates on CXR

**LUNG PROTECTIVE VENTILATION**
- VT 4-6 ml/kg predicted body weight
- Plateau pressure <30
- Driving pressure (Pplat-PEEP) <15
- Target SaO₂ 90-96%, PaO₂>60
- Starting PEEP 8-10 cmH₂O

**CONSERVATIVE FLUID STRATEGY**
- Diuresis as tolerated by hemodynamics

**PEEP TITRATION**
Best PEEP by tidal compliance or ARDS net low PEEP

**PRONE**
Early consideration if cont. hypoxemia or elevated airway pressures

**ADDITIONAL THERAPIES**
Paralytics for vent dysynchrony, not routine
Inhaled NO up to 80 ppm (no epoprostenol)

**ECMO CONSULT** (available at limited centers)
If continuous hypoxemia or elevated airway pressure...
Special Considerations:

For intubation:
- Perform in negative pressure room whenever possible.
- PPE should include N95 respirator with face shield/protective eyewear (personal eyeglasses not adequate), isolation gowns (yellow gowns) for high risk aerosolizing procedures/impermeable to secretions and contact precautions. Intubate early/electively to avoid emergent intubation.
- Avoid noninvasive ventilation.
- Avoid bag mask ventilation of patients.
- Pre-oxygenate with nasal cannula and face masks as needed.
- Use rapid sequence induction and intubation with early use of paralytics.
- Consideration for shoe covers and surgical hoods or caps to avoid droplet contamination is reasonable.
- Avoid shortage of mechanical ventilators and crisis standard of care.

For Bronchoscopy:
- Limit procedures, only perform if absolutely necessary.
- Perform in negative pressure room.
- PPE as per intubation.

Noninvasive Ventilation (NIV: BPAP and CPAP) and Hi-flow Nasal Cannula (HFNC): Noninvasive ventilation to be avoided because of it being highly aerosolizing.
- If NIV cannot be avoided due to respiratory distress or obstructive sleep apnea (OSA), a pulmonary/critical care consult is required for further recommendations.
- Patients on NIV should remain in a negative pressure room with all personnel using appropriate well fit N-95/PPE.
- This includes patients being transported between facilities.

Hi-flow nasal cannula (HFNC) has conflicting literature:
- If patient dependent and appropriate for intubation, intubate
- Avoid hi flows of oxygen unless necessary.
- May consider use of hi oxygen flows (over 6 l/m) or HFNC in negative pressure room, with all personnel using appropriate well fit N-95/PPE.

Bronchodilators:
- Avoid nebulization in non-intubated confirmed COVID-19 patients unless needed due to bronchospasm/asthmatic patients.
• Metered Dose Inhalers (MDIs) recommended for non-intubated patients, whether in ER or admitted.
• MDIs should be stored in wiped-clean closed plastic bag.
• Nebulization may be performed on intubated COVID-19 patients if the patient was prescribed an MDI prior to intubation.
• When administering an MDI, a face shield/protective eyewear (personal eyeglasses not adequate) and N95 mask are required.

**Discharge Criteria:**
• Improvement of respiratory symptoms.
• Afebrile for at least 3 days.
• Chest x ray shows improvement in infiltrates.
• Documented virological clearance (negative PCR) in 2 samples at least 24 hours apart.
• Maintaining oxygen saturation >90% on room air.

**Prevention in Health Care Settings:**

**Regular Hand Washing:**
The CDC recommends regular hand washing with soap and water for at least 20 seconds and if soap and water are not available, use an alcohol-based hand sanitizer with at least 60% alcohol.

**PPE Use in Different Clinical Areas:**

<table>
<thead>
<tr>
<th>Screening areas at the entry of health care facility</th>
<th>Surgical mask</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health care providers in <strong>clinics</strong></td>
<td>Gown and surgical mask</td>
</tr>
<tr>
<td>High risk <strong>screening areas/triage</strong> for COVID-19 suspect cases</td>
<td>Full sleeved impervious gowns, gloves, surgical mask</td>
</tr>
<tr>
<td>Areas where COVID-19 suspected and positive <strong>patient admitted</strong></td>
<td>Full sleeved impervious gowns, gloves, N95 mask and goggles/ full face wiser</td>
</tr>
<tr>
<td>Areas where <strong>aerosol generating procedures</strong> are performed like bronchoscopy, suctioning and nebulizations</td>
<td>Full sleeved impervious gowns, gloves, N95 mask and goggles/ full face wiser</td>
</tr>
</tbody>
</table>
References:


18. WHO Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. WHO/2019-nCoV/clinical/2020.4
## Appendix:
### Advantages & disadvantages of various diagnostic interventions

<table>
<thead>
<tr>
<th></th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of travel from abroad</td>
<td>Easy to collect. Helpful in picking high risk people. Helpful in limiting the spread by self-quarantine measures.</td>
<td>People hide travel history. May be too late to self-quarantine as the disease has already spread. Not everyone will have the disease. Only 25% of Iran Zaireen had the disease.</td>
<td>Data should always be collected.</td>
</tr>
<tr>
<td>Contact with positive patient</td>
<td>Very helpful in identifying the high risk individual. Helpful in limiting the spread by self-quarantine measures.</td>
<td>Unknown contacts will be missed. People recall may not lead to listing of all. All contacts may not be traced.</td>
<td>Data should always be collected.</td>
</tr>
<tr>
<td>Typical flu symptoms</td>
<td>Can help in the picking of suspected cases</td>
<td>Not specific as other conditions may present like this.</td>
<td></td>
</tr>
<tr>
<td>CBC</td>
<td>Easy to perform. Widely available. The changes due to Covid-19 are known</td>
<td>It is not specific. It can be higher or lower depending on individual patients. It does not confirm the diagnosis.</td>
<td>Must test in all the patients.</td>
</tr>
<tr>
<td>C-reactive protein (CRP)</td>
<td>Easy to do. Widely available. Varies in relation to the severity of the disease</td>
<td>It is nonspecific and non-diagnostic. Can be higher in other infections as well.</td>
<td>Useful test in admitted patients.</td>
</tr>
<tr>
<td>HRCT</td>
<td>Can be positive in the early stage. It can show changes in almost all the cases. There is good correlation with gold standard RT-PCR test. It can show progression and improvement through serial scans.</td>
<td>It is time consuming. Not widely available. It is non-specific as similar changes can be present in the other conditions. It will require dedicated CT scanner to prevent cross infection.</td>
<td>A very useful test where it can be performed safely.</td>
</tr>
<tr>
<td>SARS-CoV-2 RNA detection by reverse-transcription polymerase chain reaction (RT-PCR)</td>
<td>It is a diagnostic test when positive. Serial testing can declare patient cured. It can help in rapid diagnosis compared to gene sequencing.</td>
<td>Require invasive means to collect specimens. High chances of cross infection. Will need to be repeated as single specimen may not be positive. Multiple specimens will need to be tested from different sites. The Turn Around Time (TAT) will be in days. It will require specialized setup for reliable testing and safety measures. Kits supply can be the limiting factor.</td>
<td>It is a must test and gold standard at the moment.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>
Suggested Reading: